Nowakowski, Grzegorz S. http://orcid.org/0000-0002-6955-9393
Yoon, Dok Hyun
Mondello, Patrizia
Joffe, Erel
Peters, Anthea
Fleury, Isabelle
Greil, Richard
Ku, Matthew
Marks, Reinhard
Kim, Kibum
Zinzani, Pier Luigi
Trotman, Judith
Sabatelli, Lorenzo
Waltl, Eva E.
Winderlich, Mark
Sporchia, Andrea
Kurukulasuriya, Nuwan C.
Cordoba, Raul
Hess, Georg
Salles, Gilles
Funding for this research was provided by:
MorphoSys
Article History
Received: 25 May 2022
Accepted: 23 March 2023
First Online: 12 May 2023
Change Date: 11 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00277-023-05321-3
Statements and declarations
:
: The RE-MIND2 protocol was submitted to and approved by, or received a favorable opinion from, an Institutional Review Board (IRB) or Independent Ethics Committee according to national or local regulations. Any protocol amendments were also submitted for relevant approval.
: Where applicable, written informed consent (approved by an independent ethics committee [IEC]/IRB) was obtained from patients prior to data collection. A waiver of consent was obtained from the responsible IEC/IRB in accordance with local laws or regulations for the following countries: Australia, Austria, Canada, Denmark, Republic of Korea, Taiwan, and the United States. In accordance with French declaration of conformity MR-004 for research that reuses data, a Patient Information Sheet was used to inform patients.
: This study was designed, implemented, and reported in accordance with Guidelines for GoodPharmacoepidemiology Practices, Section 4.9.5 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use GoodClinical Practices guidelines and the ethical principles laid down in the Declaration of Helsinki.
: <b>Grzegorz S. Nowakowski:</b> Consultancy and Membership on an entity’s Board of Directors or advisory committees: Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite/Gilead; Research Funding: Celgene, NanoString Technologies, MorphoSys. <b>Dok Hyun Yoon:</b> No disclosure. <b>Patrizia Mondello:</b> No disclosure. <b>Erel Joffe:</b> Consultancy: AstraZeneca, Epizyme. <b>Anthea Peters:</b> Consultancy and Honoraria: AbbVie, Incyte. <b>Isabelle Fleury:</b> Conference and advisory role: AbbVie, AstraZeneca, BMS, Celgene, Janssen, Kite-Gilead, Merck, Novartis, Roche, Seattle Genetics. <b>Richard Greil:</b> Honoraria: Amgen, Sandoz, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Other (travel, accommodations, expenses): Amgen, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Research Funding: Amgen, Sandoz, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Consultancy: Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Membership on an entity’s Board of Directors or advisory committees: Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene. <b>Matthew Ku:</b> Consultancy: Roche, Antegene, Genor Biopharma. <b>Reinhard Marks:</b> Membership on an entity’s Board of Directors or advisory committees: Kite/Gilead; Other (meeting attendance): AbbVie; Honoraria: Kite/Gilead; Consultancy: Merck. <b>Kibum Kim:</b> Research funding: AstraZeneca. <b>Pier Luigi Zinzani:</b> Consultancy: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Sanofi; Membership on an entity’s Board of Directors or advisory committees: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Portola, Sanofi, AbbVie; Speakers Bureau: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Portola, AbbVie; Honoraria: Bristol Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Kyowa Kirin, Roche, Verastem, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, AbbVie; Research funding: Portola. <b>Judith Trotman:</b> Research funding: BeiGene, Celgene, Bristol-Myers Squibb, Roche, Janssen, PCYC Pharmacyclics. <b>Lorenzo Sabatelli:</b> Employee and equity holder of Incyte Biosciences International. <b>Eva E. Waltl:</b> Employee of MorphoSys AG. <b>Mark Winderlich</b>: Employee of MorphoSys AG with stock options, patents, and royalties. <b>Andrea Sporchia:</b> Employee of MorphoSys AG. <b>Nuwan C. Kurukulasuriya:</b> Employee and equity holder of MorphoSys AG with meetings/travel support provided by MorphoSys AG. <b>Raul Cordoba:</b> Research Funding: Pfizer; Membership on an entity’s Board of Directors or advisory committees: Kyowa-Kirin, Roche, AbbVie, ADC Therapeutics, Bristol-Myers Squibb, Incyte, Takeda, Janssen, Kite; Speakers Bureau: Roche, AbbVie, Bristol-Myers Squibb, Takeda, Janssen, Kite. <b>Georg Hess:</b> Honoraria: Roche, Janssen, Incyte, AbbVie, AstraZeneca, Genmab, Gilead, EUSA; Membership on an entity’s Board of Directors or advisory committees: Roche, Janssen, Incyte, AbbVie, AstraZeneca, Genmab, Gilead, EUSA; Research Funding: Roche, Janssen, Incyte, AbbVie, Gilead/Kite. <b>Gilles Salles:</b> Consultancy: Genmab, Epizyme, Roche/Genentech, Janssen, Ipsen, Novartis, Bristol-Myers Squibb/Celgene, BeiGene, AbbVie, Kite/Gilead, Incyte, Debiopharm, Loxo, Miltenyi, MorphoSys AG, Rapt, Regeneron, Takeda, Velosbio, Allogene; Membership on an entity’s Board of Directors or advisory committees: Genmab, Epizyme, Janssen, Roche/Genentech, Novartis, BeiGene, Kite/Gilead, Incyte, Debiopharm, Loxo, MorphoSys AG, Rapt, Takeda, Velosbio; Honoraria: Epizyme, Janssen, Bristol-Myers Squibb/Celgene, AbbVie, Bayer, MorphoSys AG, Regeneron.